Johnson & Johnson logo
Johnson & Johnson (JNJ)
Compare

Johnson & Johnson (JNJ) Earnings Yield: 3.60%

Is Johnson & Johnson’s earnings yield high or low?

Johnson & Johnson's earnings yield of 3.60% is 31% below its 5-year average of 5.19%, near the low end of its 5-year range (2.74%–10.52%).

As of Thursday, June 11, 2026. 26.50% below its 12-month average of 4.90%.

JNJ Earnings Yield Chart

JNJ Earnings Yield
3.60%-37.82% 1Y
Zoom

JNJ Average Earnings Yield Chart

JNJ Current vs Average Earnings Yield Chart

JNJ Earnings Yield Metrics

EARNINGS YIELD

3.60%

EARNINGS YIELD AVG TTM

4.90%

EARNINGS YIELD AVG 3Y

5.96%

EARNINGS YIELD AVG 5Y

5.19%

EARNINGS YIELD AVG 10Y

4.40%

EARNINGS YIELD AVG 15Y

4.70%

EARNINGS YIELD AVG 20Y

5.22%

CURRENT VS TTM AVG

-26.50%

CURRENT VS 3Y AVG

-39.62%

CURRENT VS 5Y AVG

-30.66%

CURRENT VS 10Y AVG

-18.16%

CURRENT VS 15Y AVG

-23.44%

CURRENT VS 20Y AVG

-30.98%

JNJ Competitors' Earnings Yield

NAMEMARKET CAPEARNINGS YIELDTTM3Y5Y
Johnson & Johnson (JNJ)$577.73B3.60%4.90%5.96%5.19%
Pfizer Inc. (PFE)$149.61B4.99%6.28%6.38%7.46%
Merck & Co., Inc. (MRK)$298.23B2.94%6.88%4.56%4.76%
AbbVie Inc. (ABBV)$399.86B0.90%0.93%1.66%2.60%
Eli Lilly and Company (LLY)$1.10T2.42%2.11%1.42%1.71%
Bristol-Myers Squibb Company (BMY)$116.13B6.26%5.70%6.24%5.43%

Earnings Yield vs P/E Ratio

Earnings Yield

3.60%

EPS ÷ Price

P/E Ratio

27.8

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

  • It expresses earnings relative to share price as a percentage
  • It can be compared with FCF yield and dividend yield
  • It can be compared with bond yields because both are percentages
  • It is mathematically the inverse of the P/E ratio

Johnson & Johnson Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Johnson & Johnson Earnings Yield FAQ

What is the earnings yield for Johnson & Johnson (JNJ)?
The earnings yield for JNJ stock is 3.60%.
Is Johnson & Johnson's earnings yield high or low?
Johnson & Johnson's earnings yield of 3.60% is 31% below its 5-year average of 5.19%, near the low end of its 5-year range (2.74%–10.52%).
What is the TTM average earnings yield for Johnson & Johnson (JNJ)?
The TTM average earnings yield for JNJ stock is 4.90%.
What is the 3Y average earnings yield for Johnson & Johnson (JNJ)?
The 3Y average earnings yield for JNJ stock is 5.96%.
What is the 5Y average earnings yield for Johnson & Johnson (JNJ)?
The 5Y average earnings yield for JNJ stock is 5.19%.
What is the 10Y average earnings yield for Johnson & Johnson (JNJ)?
The 10Y average earnings yield for JNJ stock is 4.40%.
What is the 15Y average earnings yield for Johnson & Johnson (JNJ)?
The 15Y average earnings yield for JNJ stock is 4.70%.
What is the 20Y average earnings yield for Johnson & Johnson (JNJ)?
The 20Y average earnings yield for JNJ stock is 5.22%.

Johnson & Johnson Earnings Yield History

DATEEARNINGS YIELD
2026-06-113.60%
2026-06-103.63%
2026-06-093.65%
2026-06-083.73%
2026-06-053.72%
2026-06-043.79%
2026-06-033.87%
2026-06-023.88%
2026-06-013.87%
2026-05-293.84%
2026-05-283.75%
2026-05-273.74%
2026-05-263.76%
2026-05-223.69%
2026-05-213.73%
2026-05-203.77%
2026-05-193.76%
2026-05-183.78%
2026-05-153.82%
2026-05-143.75%
2026-05-133.75%
2026-05-123.86%
2026-05-113.91%
2026-05-083.91%
2026-05-073.89%
2026-05-063.85%
2026-05-053.83%
2026-05-043.86%
2026-05-013.81%
2026-04-303.76%
2026-04-293.81%
2026-04-283.80%
2026-04-273.84%
2026-04-243.80%
2026-04-233.75%
2026-04-223.83%
2026-04-214.89%
2026-04-204.79%
2026-04-174.72%
2026-04-164.71%
2026-04-154.63%
2026-04-144.60%
2026-04-134.64%
2026-04-104.63%
2026-04-094.58%
2026-04-084.58%
2026-04-074.63%
2026-04-064.59%
2026-04-024.55%
2026-04-014.53%
2026-03-314.52%
2026-03-304.56%
2026-03-274.60%
2026-03-264.62%
2026-03-254.61%
2026-03-244.70%
2026-03-234.69%
2026-03-204.69%
2026-03-194.65%
2026-03-184.66%
2026-03-174.64%
2026-03-164.54%
2026-03-134.57%
2026-03-124.57%
2026-03-114.55%
2026-03-104.53%
2026-03-094.56%
2026-03-064.60%
2026-03-054.61%
2026-03-044.50%
2026-03-034.48%
2026-03-024.45%
2026-02-274.45%
2026-02-264.54%
2026-02-254.51%
2026-02-244.49%
2026-02-234.49%
2026-02-204.56%
2026-02-194.48%
2026-02-184.51%
2026-02-174.54%
2026-02-134.54%
2026-02-124.52%
2026-02-114.59%
2026-02-104.35%
2026-02-094.34%
2026-02-064.32%
2026-02-054.36%
2026-02-044.42%
2026-02-034.44%
2026-02-024.49%
2026-01-304.56%
2026-01-294.56%
2026-01-284.55%
2026-01-274.62%
2026-01-264.68%
2026-01-234.71%
2026-01-224.74%
2026-01-214.75%
2026-01-204.75%
2026-01-164.74%
2026-01-154.72%
2026-01-144.74%
2026-01-134.85%
2026-01-124.94%
2026-01-095.07%
2026-01-085.04%
2026-01-074.99%
2026-01-065.06%
2026-01-055.07%
2026-01-025.00%
2025-12-315.01%
2025-12-305.01%
2025-12-294.99%
2025-12-264.99%
2025-12-244.99%
2025-12-235.04%
2025-12-225.00%
2025-12-195.02%
2025-12-184.97%
2025-12-174.93%
2025-12-164.95%
2025-12-154.84%
2025-12-124.90%
2025-12-114.93%
2025-12-105.02%
2025-12-095.18%
2025-12-085.14%
2025-12-055.13%
2025-12-045.12%
2025-12-035.05%
2025-12-025.04%
2025-12-015.05%
2025-11-285.01%
2025-11-264.99%
2025-11-255.01%
2025-11-245.03%
2025-11-215.08%
2025-11-205.10%
2025-11-195.12%
2025-11-185.18%
2025-11-175.19%
2025-11-145.29%
2025-11-135.31%
2025-11-125.33%
2025-11-115.34%
2025-11-105.50%
2025-11-075.55%
2025-11-065.54%
2025-11-055.57%
2025-11-045.54%
2025-11-035.56%
2025-10-315.49%
2025-10-305.48%
2025-10-295.55%
2025-10-285.54%
2025-10-275.44%
2025-10-245.44%
2025-10-235.38%
2025-10-225.37%
2025-10-214.87%
2025-10-204.83%
2025-10-174.84%
2025-10-164.87%
2025-10-154.89%
2025-10-144.90%
2025-10-134.90%
2025-10-104.90%
2025-10-094.89%
2025-10-084.93%
2025-10-074.95%
2025-10-064.97%
2025-10-034.96%
2025-10-025.03%
2025-10-015.03%
2025-09-305.04%
2025-09-295.15%
2025-09-265.20%
2025-09-255.26%
2025-09-245.29%
2025-09-235.29%
2025-09-225.37%
2025-09-195.31%
2025-09-185.37%
2025-09-175.28%
2025-09-165.30%
2025-09-155.27%
2025-09-125.25%
2025-09-115.24%
2025-09-105.32%
2025-09-095.28%
2025-09-085.25%
2025-09-055.24%
2025-09-045.23%
2025-09-035.25%
2025-09-025.25%
2025-08-295.28%
2025-08-285.33%
2025-08-275.29%
2025-08-265.30%
2025-08-255.24%
2025-08-225.21%
2025-08-215.22%
2025-08-205.23%
2025-08-195.26%
2025-08-185.31%
2025-08-155.29%
2025-08-145.35%
2025-08-135.36%
2025-08-125.41%
2025-08-115.38%
2025-08-085.39%
2025-08-075.45%
2025-08-065.48%
2025-08-055.48%
2025-08-045.47%
2025-08-015.59%
2025-07-315.68%
2025-07-305.59%
2025-07-295.56%
2025-07-285.62%
2025-07-255.56%
2025-07-245.52%
2025-07-235.32%
2025-07-225.35%
2025-07-215.47%
2025-07-185.49%
2025-07-175.52%
2025-07-165.46%
2025-07-155.79%
2025-07-145.73%
2025-07-115.73%
2025-07-105.70%
2025-07-095.75%
2025-07-085.77%
2025-07-075.79%
2025-07-035.76%
2025-07-025.78%
2025-07-015.77%
2025-06-305.89%
2025-06-275.90%
2025-06-265.91%
2025-06-255.90%
2025-06-245.91%
2025-06-235.94%
2025-06-206.00%
2025-06-185.96%
2025-06-175.90%
2025-06-165.79%
2025-06-135.72%
2025-06-125.74%
2025-06-115.79%
2025-06-105.75%
2025-06-095.79%
2025-06-065.80%
2025-06-055.85%
2025-06-045.87%
2025-06-035.82%
2025-06-025.78%
2025-05-305.79%

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Johnson & Johnson

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

New Brunswick, NJ
138,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato